Claims for Patent: 6,667,061

Summary for Patent: 6,667,061

Title:	Preparation of injectable suspensions having improved injectability
Abstract:	Injectable compositions having improved injectability. The injectable compositions include microparticles suspended in an aqueous injection vehicle having a viscosity of at least 20 cp at 20.degree. C. The increased viscosity of the injection vehicle that constitutes the fluid phase of the suspension significantly reduces in vivo injectability failures. The injectable compositions can be made by mixing dry microparticles with an aqueous injection vehicle to form a suspension, and then mixing the suspension with a viscosity enhancing agent to increase the viscosity of the fluid phase of the suspension to the desired level for improved injectability.
Inventor(s):	Ramstack; J. Michael (Lebanon, OH), Riley; M. Gary I. (Cambridge, MA), Zale; Stephen E. (Hopkinton, MA), Hotz; Joyce M. (Cincinnati, OH), Johnson; Olufunmi L. (Cambridge, MA)
Assignee:	Alkermes Controlled Therapeutics, Inc. (Cambridge, MA)
Application Number:	10/259,949
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,667,061
Patent Claims:	1. A composition suitable for injection through a needle into a host, comprising: microparticles comprising a polymeric binder; and an injection vehicle, wherein said microparticles are suspended in said injection vehicle at a concentration of greater than about 30 mg/ml to form a suspension, wherein a fluid phase of said suspension has a viscosity greater than about 20 cp and less than about 600 cp at 20.degree. C., wherein the viscosity of said fluid phase of said suspension provides injectability of the composition through a needle ranging in diameter from 18-22 gauge. 2. The composition of claim 1, wherein said injection vehicle comprises a viscosity enhancing agent. 3. The composition of claim 2, wherein said viscosity enhancing agent comprises sodium carboxymethyl cellulose. 4. The composition of claim 1, wherein said injection vehicle comprises a density enhancing agent. 5. The composition of claim 4, wherein said density enhancing agent comprises sorbitol. 6. The composition of claim 1, wherein said injection vehicle comprises a tonicity adjusting agent. 7. The composition of claim 6, wherein said tonicity adjusting agent comprises sodium chloride. 8. The composition of claim 2, wherein said injection vehicle further comprises a wetting agent. 9. The composition of claim 8, wherein said wetting agent is selected from the group consisting of polysorbate 20, polysorbate 40, and polysorbate 80. 10. The composition of claim 4, wherein said injection vehicle further comprises a wetting agent. 11. The composition of claim 10, wherein said wetting agent is selected from the group consisting of polysorbate 20, polysorbate 40, and polysorbate 80. 12. The composition of claim 6, wherein said injection vehicle further comprises a wetting agent. 13. The composition of claim 12, wherein said wetting agent is selected from the group consisting of polysorbate 20, polysorbate 40, and polysorbate 80. 14. The composition of claim 1, wherein the viscosity of said fluid phase of said suspension is greater than 40 cp and less than 60 cp at 20.degree. C. 15. The composition of claim 14, wherein said injection vehicle comprises 1.5% sodium carboxymethyl cellulose, 30% sorbitol, and 0.2% polysorbate 20. 16. The composition of claim 14, wherein said injection vehicle comprises 3% sodium carboxymethyl cellulose, 0.9% saline, and 0.1% polysorbate 20. 17. The composition of claim 1, wherein said microparticles further comprise an active agent encapsulated within said polymeric binder. 18. The composition of claim 17, wherein said polymeric binder is selected from the group consisting of poly(glycolic acid), poly-d,l-lactic acid, poly-l-lactic acid, copolymers of the foregoing, poly(aliphatic carboxylic acids), copolyoxalates, polycaprolactone, polydioxanone, poly(ortho carbonates), poly(acetals), poly(lactic acid-caprolactone), polyorthoesters, poly(glycolic acid-caprolactone), polyanhydrides, polyphosphazines, albumin, casein, and waxes. 19. The composition of claim 17, wherein said polymeric binder is poly(d,l-lactide-co-glycolide) having a molar ratio of lactide to glycolide in the range of from about 85:15 to about 50:50. 20. The composition of claim 17, wherein said active agent is selected from the group consisting of risperidone, 9-hydroxyrisperidone, and pharmaceutically acceptable salts thereof. 21. The composition of claim 19, wherein said active agent is selected from the group consisting of risperidone, 9-hydroxyrisperidone, and pharmaceutically acceptable salts thereof. 22. The composition of claim 1, wherein the mass median diameter of said microparticles is less than about 250 .mu.m. 23. The composition of claim 1, wherein the mass median diameter of said microparticles is in the range of from about 20 .mu.m to about 150 .mu.m.